HealthWarehouse (HEWA) AI Stock Analysis

HealthWarehouse

(Other OTC:HEWA)

Select Model

Rating:39Underperform

Price Target:$0.08▼(-5.62% Downside)

Action:reiterated

Date:10/31/26

HEWA receives a very low overall score primarily driven by severe financial distress, highlighted by negative cash flows and persistent solvency risks. Unprofitability drastically limits its valuation appeal, while technical indicators reinforce a prevailing long-term bearish trend.

Positive Factors

Online Pharmacy Business ModelThe online pharmacy model gives HealthWarehouse a direct digital channel to sell prescription and over-the-counter products to consumers. Its established e-commerce platform and permitted fulfillment capabilities provide a scalable operating foundation, although results depend on restoring financial performance.

Negative Factors

Recent Revenue ContractionThe sharp TTM revenue decline weakens the scale advantages of the online pharmacy model and reduces the revenue base available to absorb fixed operating costs. Continued contraction would make it harder to regain profitability, sustain investment, and rebuild consistent cash generation.

HealthWarehouse (HEWA) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $5.15M
Dividend Yield: ―
Average Volume (3M): 33.40K
Price to Earnings (P/E): -4.3
Beta (1Y): -0.40
Revenue Growth: -42.51%
EPS Growth: -481.03%
Country: US
Employees: 121
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Pharmaceuticals

HealthWarehouse Business Overview & Revenue Model

Company Description

HealthWarehouse.com, Inc. functions as a digital and direct-mail pharmaceutical service. Its offerings encompass a broad spectrum of pharmaceutical items, including generic and brand-name prescription drugs, specialized medications for pets, and a va...

HealthWarehouse Financial Statement Overview

Summary

Financials reflect a highly distressed profile with shrinking revenues, renewed bottom-line losses, mounting cash burn, and severe structural risks including a persistent equity deficit.

Income Statement

35Negative

Balance Sheet

15Very Negative

Cash Flow

25Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	30.73M	48.99M	33.61M	20.28M	18.14M	16.14M
Gross Profit	14.09M	17.14M	13.69M	12.17M	11.94M	11.13M
EBITDA	-292.08K	931.62K	338.42K	-1.28M	-559.33K	-224.76K
Net Income	-915.87K	265.00K	-332.97K	-1.77M	-952.03K	-572.50K
Balance Sheet
Total Assets	4.57M	5.88M	5.05M	3.21M	3.97M	3.62M
Cash, Cash Equivalents and Short-Term Investments	1.07M	2.21M	1.13M	567.96K	1.04M	2.18M
Total Debt	3.52M	2.90M	3.84M	2.09M	3.04M	2.15M
Total Liabilities	8.53M	9.18M	9.08M	7.21M	7.00M	6.41M
Stockholders Equity	-3.95M	-3.30M	-4.04M	-4.01M	-3.03M	-2.79M
Cash Flow
Free Cash Flow	-843.05K	1.06M	565.36K	-473.81K	-1.14M	313.64K
Operating Cash Flow	-783.85K	1.16M	705.26K	-163.84K	-624.45K	400.51K
Investing Cash Flow	-59.20K	-95.23K	-139.90K	-309.97K	-512.85K	-86.86K
Financing Cash Flow	0	9,000	0	0	0	0

HealthWarehouse Technical Analysis

Technical Analysis SentimentNeutral

Last Price0.09

Price Trends

50DMA0.09Positive

100DMA0.11Negative

200DMA0.11Negative

Market Momentum

MACD0.00Negative

RSI53.59Neutral

STOCH94.31Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HEWA, the sentiment is Neutral. The current price of 0.09 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.09, and below the 200-day MA of 0.11, indicating a neutral trend. The MACD of 0.00 indicates Negative momentum. The RSI at 53.59 is Neutral, neither overbought nor oversold. The STOCH value of 94.31 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HEWA.

HealthWarehouse Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

HEWA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HSCS	49Neutral	$16.45M	-1.03	-816.25%	―	-27.70%	61.44%
NDRA	45Neutral	$7.12M	-0.75	-224.80%	―	―	98.17%
LFMD	44Neutral	$110.38M	-4.51	-179.12%	―	-16.73%	-143.95%
PETS	43Neutral	$25.80M	-0.86	-91.67%	―	-19.67%	34.91%
HEWA	39Underperform	$5.14M	-4.29	25.60%	―	-42.51%	-481.03%

* Healthcare Sector Average

Performance Comparison

HEWA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
HEWA	HealthWarehousecom	0.09	-0.06	-40.27%
PETS	Petmed Express	1.19	-1.25	-51.23%
NDRA	Endra Life Sciences	4.75	-0.42	-8.12%
LFMD	Lifemd, Inc.	2.29	-3.45	-60.10%
KTTA	Pasithea Therapeutics Corp.	0.37	-0.45	-54.88%
HSCS	Heart Test Laboratories, Inc.	3.31	0.38	12.97%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026

HealthWarehouse AI Stock Analysis